347 related articles for article (PubMed ID: 19999386)
21. Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin: review of the literature.
Karthaus M
Eur J Med Res; 2011 Apr; 16(4):145-52. PubMed ID: 21486728
[TBL] [Abstract][Full Text] [Related]
22. Comparative survival and cost of antifungal therapy: posaconazole versus standard antifungals in the treatment of refractory invasive aspergillosis.
Herbrecht R; Rajagopalan S; Danna R; Papadopoulos G
Curr Med Res Opin; 2010 Oct; 26(10):2457-64. PubMed ID: 20822354
[TBL] [Abstract][Full Text] [Related]
23. An update on the use of antifungal agents.
Martinez R
J Bras Pneumol; 2006; 32(5):449-60. PubMed ID: 17268750
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.
Floros L; Kuessner D; Posthumus J; Bagshaw E; Sjölin J
BMC Infect Dis; 2019 Feb; 19(1):134. PubMed ID: 30744563
[TBL] [Abstract][Full Text] [Related]
25. [New antifungal agents: voriconazole and caspofungin].
Dupont B
Arch Pediatr; 2003 Dec; 10 Suppl 5():592s-598s. PubMed ID: 15022787
[TBL] [Abstract][Full Text] [Related]
26. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
[TBL] [Abstract][Full Text] [Related]
27. Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis.
Lewis JS; Boucher HW; Lubowski TJ; Ambegaonkar AJ; Day DL; Patterson TF
Pharmacotherapy; 2005 Jun; 25(6):839-46. PubMed ID: 15927903
[TBL] [Abstract][Full Text] [Related]
28. Deep sinus aspergillosis in a liver transplant recipient successfully treated with a combination of caspofungin and voriconazole.
Tsiodras S; Zafiropoulou R; Giotakis J; Imbrios G; Antoniades A; Manesis EK
Transpl Infect Dis; 2004 Mar; 6(1):37-40. PubMed ID: 15225226
[TBL] [Abstract][Full Text] [Related]
29. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin.
Breit SM; Hariprasad SM; Mieler WF; Shah GK; Mills MD; Grand MG
Am J Ophthalmol; 2005 Jan; 139(1):135-40. PubMed ID: 15652837
[TBL] [Abstract][Full Text] [Related]
30. Successful treatment of invasive Aspergillus sinusitis with caspofungin and voriconazole.
Chirch L; Roche P; Fuhrer J
Ear Nose Throat J; 2008 Jan; 87(1):30-3. PubMed ID: 18357943
[TBL] [Abstract][Full Text] [Related]
31. Rapid improvement of disseminated aspergillosis with caspofungin/voriconazole combination in an adult leukemic patient.
Damaj G; Ivanov V; Le Brigand B; D'incan E; Doglio MF; Bilger K; Faucher C; Vey N; Gastaut JA
Ann Hematol; 2004 Jun; 83(6):390-3. PubMed ID: 14666380
[TBL] [Abstract][Full Text] [Related]
32. Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients.
Barnes R; Earnshaw S; Herbrecht R; Morrissey O; Slavin M; Bow E; McDade C; Charbonneau C; Weinstein D; Kantecki M; Schlamm H; Maertens J
Clin Ther; 2015 Jun; 37(6):1317-1328.e2. PubMed ID: 25891805
[TBL] [Abstract][Full Text] [Related]
33. Caspofungin versus liposomal amphotericin B for empirical therapy.
Danaher PJ
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675092
[No Abstract] [Full Text] [Related]
34. Voriconazole: review of a broad spectrum triazole antifungal agent.
Kofla G; Ruhnke M
Expert Opin Pharmacother; 2005 Jun; 6(7):1215-29. PubMed ID: 15957974
[TBL] [Abstract][Full Text] [Related]
35. Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis.
Harrington R; Lee E; Yang H; Wei J; Messali A; Azie N; Wu EQ; Spalding J
Adv Ther; 2017 Jan; 34(1):207-220. PubMed ID: 27913989
[TBL] [Abstract][Full Text] [Related]
36. [Successful treatment of neuroaspergillosis in a patient with acute lymphoblastic leukemia: role of surgery, systemic antifungal therapy and intracavitary therapy].
Ozçelik T; Ozkalemkaş F; Kocaeli H; Altundal Y; Ener B; Ali R; Ozkocaman V; Hakyemez B; Tunali A
Mikrobiyol Bul; 2009 Jul; 43(3):499-506. PubMed ID: 19795628
[TBL] [Abstract][Full Text] [Related]
37. Combination antifungal therapy for invasive aspergillosis.
Marr KA; Boeckh M; Carter RA; Kim HW; Corey L
Clin Infect Dis; 2004 Sep; 39(6):797-802. PubMed ID: 15472810
[TBL] [Abstract][Full Text] [Related]
38. Combination antifungal therapy for invasive aspergillosis: utilizing new targeting strategies.
Steinbach WJ
Curr Drug Targets Infect Disord; 2005 Sep; 5(3):203-10. PubMed ID: 16181140
[TBL] [Abstract][Full Text] [Related]
39. Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy.
Stam WB; Aversa F; Kumar RN; Jansen JP
Value Health; 2008; 11(5):830-41. PubMed ID: 18494752
[TBL] [Abstract][Full Text] [Related]
40. The effects of caspofungin and voriconazole in an experimental fungal infection of the ear due to Aspergillus.
Ayçiçek A; Cetinkaya Z; Kiyici H; Kenar F; Aşik G; Kiraz N
Eur Arch Otorhinolaryngol; 2009 Nov; 266(11):1703-9. PubMed ID: 19340446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
